Association between high-sensitivity C-reactive protein and coronary plaque subtypes assessed by 64-slice coronary computed tomography angiography in an asymptomatic population. by �옣�쁺�옱
Agatston and Juan J. Rivera
Eue-Keun Choi, Sung-A. Chang, Yeonyee E. Yoon, Eun Ju Chun, Sang-il Choi, Arthur S. 
Jonathan Rubin, Hyuk-Jae Chang, Khurram Nasir, Roger S. Blumenthal, Michael J. Blaha,
Population
Assessed by 64-Slice Coronary Computed Tomography Angiography in an Asymptomatic 
Association Between High-Sensitivity C-Reactive Protein and Coronary Plaque Subtypes
Print ISSN: 1941-9651. Online ISSN: 1942-0080 
Copyright © 2011 American Heart Association, Inc. All rights reserved.
Dallas, TX 75231
is published by the American Heart Association, 7272 Greenville Avenue,Circulation: Cardiovascular Imaging 
doi: 10.1161/CIRCIMAGING.109.929901
2011;4:201-209; originally published online March 21, 2011;Circ Cardiovasc Imaging. 
 http://circimaging.ahajournals.org/content/4/3/201
World Wide Web at: 
The online version of this article, along with updated information and services, is located on the
  
 http://circimaging.ahajournals.org//subscriptions/
is online at: Circulation: Cardiovascular Imaging  Information about subscribing to Subscriptions:
  
 http://www.lww.com/reprints
 Information about reprints can be found online at: Reprints:
  
document. Permissions and Rights Question and Answer information about this process is available in the
requested is located, click Request Permissions in the middle column of the Web page under Services. Further
Center, not the Editorial Office. Once the online version of the published article for which permission is being 
 can be obtained via RightsLink, a service of the Copyright ClearanceCirculation: Cardiovascular Imagingin
 Requests for permissions to reproduce figures, tables, or portions of articles originally publishedPermissions:
 at CONS KESLI on November 3, 2013http://circimaging.ahajournals.org/Downloaded from 
Original Articles
Association Between High-Sensitivity C-Reactive Protein and
Coronary Plaque Subtypes Assessed by 64-Slice Coronary
Computed Tomography Angiography in an
Asymptomatic Population
Jonathan Rubin, MD; Hyuk-Jae Chang, MD, PhD; Khurram Nasir, MD, MPH;
Roger S. Blumenthal, MD; Michael J. Blaha, MD, MPH; Eue-Keun Choi, MD; Sung-A. Chang, MD;
Yeonyee E. Yoon, MD; Eun Ju Chun, MD; Sang-il Choi, MD;
Arthur S. Agatston, MD; Juan J. Rivera, MD, MHS
Background—Elevated levels of C-reactive protein (CRP) are associated with poor cardiovascular outcomes, even after
accounting for traditional cardiovascular risk factors. We sought to analyze the relationship between levels of CRP and
coronary plaque subtypes as assessed by coronary computed tomography angiography.
Methods and Results—We evaluated 1004 asymptomatic South Korean subjects (mean age, 499.3 years) who underwent
coronary computed tomography angiography as part of a health screening evaluation. We examined the association
between increasing CRP levels and plaque subtypes using multivariable linear and logistic regression analysis. Coronary
plaque was observed in 211 of 1004 individuals (21%). Subjects with high CRP (2 mg/L) had an increased prevalence
of any plaque type (30.7% versus 16.7% P0.001) and mixed calcified arterial plaque (MCAP) (19.3% versus 6.3%
P0.001) as compared with subjects with low-normal CRP. Multivariable logistic regression analysis demonstrated that
elevated CRP predicted the presence of any MCAP (high versus low-normal CRP group; odds ratio, 2.81; 95%
confidence interval, 1.62 to 4.89). When examining the multivariable logistic regression analysis between the presence
of 2 plaques and CRP, subjects with high CRP were more likely to have MCAP than those with low-normal CRP
levels (odds ratio, 3.78; 95% confidence interval, 1.49 to 9.55).
Conclusions—Elevated levels of CRP are associated with an increased prevalence of MCAP as assessed by coronary computed
tomography angiography. Longitudinal studies will determine if the excess risk observed in persons with elevated CRP may
be mediated, at least in part, by an increased burden of MCAP. (Circ Cardiovasc Imaging. 2011;4:201-209.)
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Risk stratification for coronary heart disease (CHD) isused to identify individuals who probably will benefit
from primary or secondary prevention therapies.1 Despite
this, the identification of subjects at increased risk of cardio-
vascular events by way of algorithms such as the Framing-
ham Risk Score has been insufficient.2–5
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Imaging has been proposed as a convenient tool to assist in
risk stratification. Coronary artery calcium scoring by computed
tomography, mainly in intermediate-risk patients, can identify
individuals at risk for coronary events and improves stratifica-
tion beyond the Framingham Risk Score6–9 but is limited by its
inability to differentiate between coronary plaque subtypes.
Coronary computed tomography angiography (CCTA)
has been shown to be a sensitive and specific tool for the
detection of significant coronary stenosis and has also
allowed for the visualization and characterization of
plaque subtypes.10 –13 Several studies have demonstrated
that CCTA can provide prognostic information14 –16 and,
most importantly, incremental prognostic value over cal-
cium scoring in patients with suspected CHD.17 Studies
have also provided insight as to what specific plaque
subtypes and characteristics might be associated with a
worse outcome.18 –21
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Concurrently, C-reactive protein (CRP) has also been
proposed as a method of identifying individuals at higher
cardiovascular risk. CRP is produced and secreted from the
liver and smooth muscle cells surrounding atherosclerotic
plaques.22 Studies have demonstrated that CRP correlates
with various aspects of atherogenesis.23,24 Although there is
ongoing debate regarding the causative role of CRP in the
development of atherosclerosis, it has been demonstrated that
CRP allows for independent25,26 and improved27–30 risk strat-
ification beyond traditional risk scoring systems. A recent
trial underscored the importance of CRP in risk stratification
by demonstrating that treating patients considered at low risk
with “near optimal lipid levels” but elevated CRP reduced
cardiovascular event rates and, most importantly, reduced
all-cause mortality.31
The role of CRP in cardiovascular risk stratification has
been clearly established, and thus we sought to analyze the
cross-sectional relationship between elevated levels of CRP
and plaque subtypes as identified by CCTA.
Methods
Study Population
We retrospectively enrolled 1043 consecutive South Korean individuals
who had undergone CCTA evaluation, using 64-slice multidetector CT
as part of a general routine health evaluation in the Seoul National
University Bundang Hospital (SNUBH) between December 2005 and
May 2006. An initial evaluation of this subject population has been
published elsewhere.32 For the present analysis, we excluded 11 indi-
viduals who had no CRP data and 28 who had missing risk factor
information. As a result, a total of 1004 self-referred, middle-aged,
asymptomatic subjects were finally enrolled. The institutional review
board approved the study protocol, and all patients gave written
informed consent.
Risk Factor Assessment and Stratification
Basic demographic data were acquired from a data base maintained
by the SNUBH Health Promotion Center. All individuals were asked
whether they had chest pain or equivalent symptoms according to a
Rose angina questionnaire.33 Medical history of myocardial infarc-
tion, angina, hypertension, stroke, diabetes mellitus (DM), family
history of premature CHD (CHD in male first-degree relative age
55 years; CHD in female first-degree relative age 65 years),
current medication profile, smoking, and social status were system-
atically acquired. Body weight, height, and blood pressure were also
measured during their visit.
Hypertension was defined as a self-reported history of hyperten-
sion and/or use of antihypertensive medication, or a blood pressure
140/90 mm Hg. Total cholesterol, triglycerides, high-density lipo-
protein cholesterol, low-density lipoprotein cholesterol, fasting blood
glucose, HbA1c, blood urea nitrogen, and serum creatinine level were
measured after at least a 12-hour fasting period on the same day of the
study. DM was defined as a self-reported history of DM and/or use of
antidiabetic medication, or a fasting glucose 126 mg/dL.
Serum CRP was measured by latex agglutination with CRP-LATEX
2 reagent (Denka Seiken Tokyo, Japan), using a chemistry autoana-
lyzer (Toshiba-200 FR, Tokyo, Japan) at the laboratory of SNUBH. The
lower limit of detection of the assay used was 0.1 mg/L. Between days,
imprecision rates were 1.94% and 2.11% for low- and high-level
controls, respectively. The coefficients of variation for monthly means
of controls were 4.2% and 1.1% for low- and high-level controls,
respectively.
Data Acquisition
Patients with a heart rate 70 beats per minute received intravenous
esmolol, 10 to 30 mg (Jeil Pharm Co, Ltd, Seocho gu, Korea), before
image acquisition. CCTA was performed with the use of a 64-slice
multidetector scanner (Brilliance 64; Philips Medical Systems, Best,
The Netherlands). A standard scanning protocol was applied, with
640.625 mm section collimation, 420-ms rotation time, 120-kV
tube voltage, and 800-mA tube current. All scans were performed
using ECG-gated dose modulation. A bolus of 80 mL Iomeprol
(Iomeron 400; Bracco, Milan, Italy) was intravenously injected (4
mL/s) followed by a 50-mL saline chaser. The average heart rate
during the scan was 587 (40 to 81) beats per minute.
A region of interest was placed in the descending thoracic aorta,
and image acquisition was automatically initiated once a selected
threshold (150 Hounsfield units) had been reached using bolus
tracking. The patient’s ECG was simultaneously recorded to allow
for retrospective segmental data reconstruction. Images were initially
reconstructed at mid-diastolic phase (75% of R-R interval) of the
cardiac cycle. Additional reconstructions were performed if motion
artifacts were present. The mean radiation exposure of CCTA was
13.210.82 mSv (13.20.8 for male and 13.30.8 for female).
Image Analysis
All scans were analyzed independently by 2 experienced radiologists
who were blinded to the clinical information, using a 3D workstation
(Brilliance; Philips Medical Systems, Best, The Netherlands). After
making independent evaluations, a consensus interpretation was arrived
at to obtain a final CCTA diagnosis. Each lesion was identified using a
multiplanar reconstruction technique and maximum intensity projection
of short-axis, 2-chamber, and 4-chamber views.
We analyzed plaque characteristics on a per-segment basis accord-
ing to the modified American Heart Association classification.34
Image quality was evaluated on a per-segment basis and classified as
good (no artifact), adequate (defined as the presence of image-
degrading artifacts but feasible for evaluation with a moderate
confidence), or poor (the presence of image-degrading artifacts and
feasible for evaluation only with a low confidence).
The contrast-enhanced portion of the coronary lumen was semi-
automatically traced at the maximal stenotic site and compared with
the mean value of proximal and distal nondiseased reference site. If
the image was adequate or poor quality, coronary segments were
visually scored for the grading of coronary artery stenosis. Each
lesion identified was examined using maximum intensity projection
and multiplanar reconstruction techniques on short axis and along
multiple longitudinal axes. Lesions were classified by the maximal
luminal diameter stenosis seen on any plane and the severity of
diameter stenosis was graded as normal-appearing (0% to 24%),
mild (25% to 49%), moderate (50% to 74%), and severe (75%)
narrowing. A stenosis of 50% and 75% was defined as significant
and severe, respectively.
Coronary plaques were defined as structures 1 mm2 within
and/or adjacent to the vessel lumen, which could be clearly distin-
guished from the lumen and surrounding pericardial tissue. Plaques
occupied by calcified tissue 50% of the plaque area (density 130
Hounsfield units in native scans) were classified as calcified arterial
plaques (CAP), plaques with 50% calcium as mixed calcified
plaques (MCAP), and plaques without any calcium were classified as
noncalcified plaques (NCAP) as previously described.11 This was
evaluated in a visual qualitative manner. We defined coronary plaque
subtype burden as the presence of 2 or more involved segments.
Coronary artery segment image quality was classified as good in
95%, adequate in 4%, and poor in 1%. Poor image quality was due
to motion artifact (55%, 121 of 219 segments), blooming artifact
(29%, 64 of 219 segments), or low contrast-to-noise ratio (16%, 34
of 219 segments). Interobserver and intraobserver agreement for the
categorical classification of stenosis were 0.87 and 0.95, respectively
(Cohen ). For the evaluation of coronary artery stenosis, we quantita-
tively measured the degree of stenosis in segments with good image
quality. If image quality was graded as adequate or poor, the degree of
stenosis was visually scored. Thus all segments were analyzed for
degree of stenosis. However, for plaque subtype analysis, we only
evaluated segments with good image quality. Interobserver agreement
for the detection of any plaque/subject and plaque/segment was excel-
lent (Cohen k0.93 and 0.84, respectively).
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Statistical Analysis
Because more than half of our study population (58%) had CRP
values of 1.0 mg/L, this was categorized as our reference group.
Individuals with CRP 1 mg/L were further divided into 2 groups
according to their median cutoff value into an intermediate CRP
group (1 to 1.9 mg/L) and a high CRP group (2 mg/L).
Continuous variables were expressed as means and standard
deviation (SD), whereas categorical variables were presented as
absolute values and percentages. Differences across CRP groups
were analyzed by ANOVA for continuous variables and 2 testing
for categorical variables.
Multivariable linear and logistic models were used to examine
the association between increasing categories of CRP and the
presence of any plaque, 2 plaques, extent of plaque, and degree
of stenosis. Ordinal logistic regression models were used to assess
the relation between CRP categories and increasing categories of
coronary artery disease (no plaque, nonobstructive, and obstruc-
tive plaque) with reference group being those with no plaque.
Ordinal regression permits logistic regression allows for 2 (in
this case, 3) categorical responses variables. Plaques were ana-
lyzed on a per-patient level, and initial analysis was unadjusted
and progressively adjusted for age and sex (model 1) and
additionally for low-density lipoprotein cholesterol, high-density
lipoprotein cholesterol, triglycerides, body mass index, smoking,
DM, and family history of premature CHD (model 2). We also
included a separate model (model 3) adjusting only for the
Framingham Risk Score. All statistical analyses were performed
using STATA version 10.0 (Austin, TX), and a probability value
of 0.05 was considered statistically significant.
Results
Baseline Characteristics
We evaluated a total of 1004 individuals. Baseline character-
istics according to CRP groups are listed in Table 1. Mean
age was 48.69.3 years (64% men), and body mass index
was 24.13 kg/m2 overall and higher in the high CRP group.
Compared with subjects in the low-normal CRP group, those
in the high CRP category were more frequently male (74%
versus 56%), smokers (44% versus 29%), hypertensive (24%
versus 16%), diabetic (14% versus 7%), and had higher levels
of both LDL-C (12334 versus 11731 mg/dL) and triglyc-
erides (153100 versus 12077 mg/dL).
Table 1. Baseline Characteristics of the Study Groups
Characteristic
Total
(n1004)
Low-Normal CRP
(n592)
Intermediate CRP
(n220)
High CRP
(n192)
P Value
(Overall)
P Value (Intermediate
Versus Normal)
P Value (High
Versus Intermediate)
Age, y 48.69.3 49.610.2 49.010.2 50.29.3 0.10
Sex, male % 64% 56% 75% 74% 0.001 0.001 0.90
BMI, kg/m2 24.12.7 23.62.6 24.82.5 25.02.9 0.001 0.001 1.00
Smoking, % 35% 29% 43% 44% 0.001 0.001 0.83
Family history of
premature CAD
13% 14% 12% 11% 0.68
Hypertension, % 20% 16% 28% 24% 0.001 0.001 0.39
Systolic blood
pressure, mm Hg
11614 11414 11815 11715 0.001 0.001 1.00
Diabetes, % 9% 7% 12% 14% 0.004 0.011 0.70
LDL-C, mg/dL 11732 11731 11533 12334 0.028 1.00 0.037
HDL-C, mg/dL 6014 6214 5813 5513 0.001 0.001 0.12
Triglycerides, mg/dL 13490 12077 153104 153100 0.001 0.001 1.00
BMI indicates body mass index; LDL-C, low-density lipoprotein cholesterol; and HDL-C, high-density lipoprotein cholesterol.
Data are expressed as proportions (%) or meanSD.
Low-normal high-sensitivity (hs)CRP: 1.0 mg/L; intermediate hsCRP: 1.1 to 2.0 mg/L; and high hsCRP: 2.0 mg/L.
Figure 1. Examples of CCTA images demonstrating the plaque subtypes analyzed. A, Normal; B, Non-Calcified Coronary Plaque
(NCAP); C, Mixed-calcified Plaque (MCAP); and D, Calcified Coronary Plaque (CAP).
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Prevalence of Coronary Plaque and Plaque Subtype
Figure 1 demonstrates the 3 coronary plaque subtypes ana-
lyzed in our study. A total of 211 patients (21%) had coronary
artery disease by CCTA. The total number of subjects in our
cohort with nonobstructive disease was 160 (16%), and 51
(5%) had significant stenosis. The most common plaque
subtype was MCAP, followed by CAP and then NCAP (10%,
9%, and 8%, respectively). Figure 2 demonstrates the prev-
alence of any coronary plaque subtype according to CRP
levels. Subjects with high CRP were more likely to have any
plaque, MCAP (P0.001), or NCAP (P0.024) as compared
with those with normal levels. A statistically significant
association was not found for CAP.
Figure 3 demonstrates the associations between the pres-
ence of 2 coronary segments with the different plaque
subtypes and CRP levels. Similar to Figure 1, a statistically
significant association was found between high CRP and the
presence of 2 coronary segments with any plaque, NCAP,
CAP, or MCAP.
Figure 4 shows the percentage of individuals with no
plaque, nonobstructive plaque, or stenosis in each CRP group.
Increasing CRP was associated with greater prevalence of
both nonobstructive and stenotic plaque.
Multivariable Analysis
Both the unadjusted and the multivariable logistic regression
analyses for the presence of any coronary plaque and plaque
subtype are listed in Table 2. Subjects were divided into
groups according to CRP levels, and all analyses were
performed using the low-normal CRP group as the reference
category. Subjects with high CRP were observed to be at
increased risk for the presence of any plaque type in the fully
adjusted model (odds ratio [OR], 1.66; 95% confidence
interval [CI], 1.08 to 2.56). Similar results were obtained after
adjusting for the Framingham Risk Score (model 3).
When examining the presence of a specific plaque subtype,
subjects with high CRP had an increased risk for the presence
of MCAP for both the unadjusted and the adjusted values.
(OR for the fully adjusted model, 2.81; 95% CI, 1.62 to 4.89).
No difference was observed in the risk for NCAP or CAP.
Similar results were obtained after adjusting for the Framing-
ham Risk Score (model 3).
The results of the unadjusted and the multivariable
logistic regression analyses for the presence of 2 seg-
ments with coronary plaque are listed in Table 3. In both
the unadjusted and fully adjusted models, subjects with
Figure 3. Percentage of individuals with 2 segments with a
coronary plaque subtype according to CRP category. Subjects
with high levels of high-sensitivity (hs)CRP were more likely to
have 2 coronary segments with any plaque, NCAP, CAP, or
MCAP. Asterisk denotes within-group comparison probability
value 0.05.
Figure 4. Percentage of individuals with no plaque, nonobstruc-
tive plaque, or stenosis, according the CRP category. Increasing
levels of high-sensitivity (hs)CRP was associated with greater
prevalence of both nonobstructive and stenotic plaque. Asterisk
denotes within-group comparison probability value 0.05.
Figure 2. Percentage of individuals with any plaque subtype
according to CRP category. Subjects with high levels of high-
sensitivity (hs)CRP were more likely to have any plaque, NCAP,
or MCAP as compared with the first and second tertiles. A sta-
tistically significant association was not found for CAP. Asterisk
denotes within-group comparison probability value 0.05.
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high CRP were observed to be at increased risk for the
presence of 2 segments of any plaque type (fully
adjusted OR, 2.03; 95% CI, 1.15 to 3.57). Similar results
were obtained after adjusting for the Framingham Risk
Score (model 3).
When examining for the presence of 2 segments of a
specific plaque subtype, subjects with high CRP had an in-
creased risk for the presence of MCAP for both the unadjusted
and the fully adjusted models. (OR for the adjusted model, 3.78;
95% CI, 1.49 to 9.55). No difference was observed in the risk for
NCAP or CAP. Similar results were obtained after adjusting for
the Framingham Risk Score (model 3).
The results of the ordinal regression analyses for an increasing
burden of obstructive disease are shown in Table 4. In both the
Table 2. Presence of Coronary Plaque and Individual Plaque Subtype
Presence of
Coronary Plaque
(No. Plaques/
No. Patients)
Unadjusted
OR (95% CI)
Model 1
OR (95% CI)
Model 2
OR (95% CI)
Model 3
OR (95% CI)
Any plaque type
Low-normal CRP 99/592 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Intermediate CRP 53/220 1.58 (1.08, 2.31) 1.26 (0.83, 1.91) 1.15 (0.75, 1.77) 1.35 (0.91, 2.00)
High CRP 59/192 2.21 (1.52, 3.21) 1.81 (1.19, 2.74) 1.66 (1.08, 2.56) 1.63 (1.09, 2.44)
Noncalcified
Low-normal CRP 39/592 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Intermediate CRP 15/220 1.04 (0.56, 1.92) 0.82 (0.44, 1.54) 0.76 (0.40, 1.44) 0.90 (0.48, 1.69)
High CRP 24/192 2.03 (1.18, 3.47) 1.60 (0.92, 2.78) 1.47 (0.83, 2.61) 1.54 (0.88, 2.70)
Mixed
Low-normal CRP 37/592 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Intermediate CRP 30/220 2.37 (1.42, 3.94) 1.97 (1.15, 3.39) 1.72 (0.97, 3.02) 2.05 (1.21, 3.46)
High CRP 37/192 3.58 (2.20, 5.84) 3.09 (1.83, 5.22) 2.81 (1.62, 4.89) 2.61 (1.55, 4.37)
Calcified
Low-normal CRP 48/592 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Intermediate CRP 20/220 1.13 (0.66, 1.96) 0.85 (0.48, 1.52) 0.80 (0.44, 1.45) 0.95 (0.54, 1.67)
High CRP 19/192 1.24 (0.71, 2.17) 0.92 (0.51, 1.67) 0.85 (0.46, 1.56) 0.84 (0.47, 1.53)
Model 1: Adjusted for age and sex.
Model 2: Adjusted for age, sex, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, body mass
index, smoking, DM, and family history of premature CHD.
Model 3: Adjusted for the Framingham Risk Score.
Table 3. Burden of Coronary Plaque and Individual Plaque Subtype
Presence of
Coronary Plaque
(No. Plaque/
No. Patients)
Unadjusted
OR (95% CI)
Model 1
OR (95% CI)
Model 2
OR (95% CI)
Model 3
OR (95% CI)
Any plaque type
Low-normal CRP 42/592 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Intermediate CRP 23/220 1.46 (0.85, 2.50) 1.11 (0.62, 2.00) 1.03 (0.56, 1.89) 1.20 (0.69, 2.11)
High CRP 32/192 2.62 (1.60, 4.29) 2.18 (1.27, 3.74) 2.03 (1.15, 3.57) 1.79 (1.06, 3.04)
Noncalcified
Low-normal CRP 7/592 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Intermediate CRP 3/220 1.16 (0.30, 4.51) 1.01 (0.26, 3.98) 0.87 (0.21, 3.56) 0.99 (0.25, 3.89)
High CRP 6/192 2.70 (0.89, 8.12) 2.33 (0.76, 7.11) 1.97 (0.61, 6.37) 1.91 (0.61, 6.04)
Mixed
Low-normal CRP 10/592 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Intermediate CRP 11/220 3.06 (1.28, 7.32) 2.42 (0.97, 6.00) 2.53 (0.98, 6.57) 2.54 (1.04, 6.20)
High CRP 14/192 4.58 (2.00, 10.48) 3.81 (1.60, 9.10) 3.78 (1.49, 9.55) 2.85 (1.19, 6.82)
Calcified
Low-normal CRP 15/592 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Intermediate CRP 4/220 0.71 (0.23, 2.17) 0.50 (0.16, 1.57) 0.48 (0.15, 1.55) 0.60 (0.20, 1.86)
High CRP 7/192 1.46 (0.58, 3.62) 1.06 (0.41, 2.76) 1.05 (0.40, 2.79) 1.02 (0.39, 2.64)
Model 1: Adjusted for age and sex.
Model 2: Adjusted for age, sex, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, body mass
index, smoking, DM and family history of premature CHD.
Model 3: Adjusted for the Framingham Risk Score.
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unadjusted and the fully adjusted models, compared with sub-
jects with low-normal CRP, those with high CRP were at
increased odds for an increasing burden of obstructive disease
(OR for the adjusted model, 1.71; 95% CI, 1.13 to 2.58).
Table 5 shows the results of multivariable linear regression
analyses for the association between increasing CRP and the
extent of any plaque or plaque subtype.  coefficients
represent the predicted increase of involved coronary seg-
ments associated with intermediate and high CRP levels, with
low-normal CRP values as the reference category. In the
unadjusted model, high CRP was associated with greater
number of coronary segments with any plaque as well as with
all the individual plaque subtypes. In the fully adjusted
model, high CRP was only associated with the extent of any
plaque and with MCAP.
In subgroup analysis, we explored the association between
increasing CRP levels and the presence of exclusively non-
calcified plaque. In both the unadjusted and the age- and
sex-adjusted models, high CRP was associated with a greater
odds of NCAP as compared with subjects with low-normal
CRP (OR for the age- and sex-adjusted models, 1.80; 95% CI,
1.02 to 3.19). This association was no longer statistically
significant after fully adjusting for other confounders (model 2).
Discussion
To the best of our knowledge, this is the first study to
systematically examine the association between CRP and
coronary plaque subtypes using CCTA in a large cohort of
asymptomatic individuals. We were able to demonstrate that
elevated levels of CRP are associated with (1) increased risk
for the presence of any plaque and MCAP but not NCAP or
CAP; (2) increased risk for the presence of 2 segments of
MCAP; and (3) significant coronary stenosis.
Inflammation is an important contributor to atherosclero-
sis. Elevated CRP, a marker of inflammation, has been clearly
related to poor cardiovascular outcomes.25–30 One of the
mechanisms by which this increased risk is thought to occur
involves increased plaque vulnerability. In an effort to di-
rectly establish the relationship between in situ plaque CRP
and plaque vulnerability, Ishikawa et al35 demonstrated
Table 4. Ordinal Regression Analyses for Increasing Burden of Obstructive Coronary Artery Disease by
CRP Levels
CRP Categories
(No. None/No.
Nonobstructive/No.
Stenotic Plaque)
Unadjusted
OR (95% CI)
Model 1
OR (95% CI)
Model 2
OR (95% CI)
Model 3
OR (95% CI)
Low-normal CRP 493/76/23 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Intermediate CRP 167/40/13 1.58 (1.09, 2.30) 1.28 (0.85, 1.92) 1.17 (0.77, 1.78) 1.37 (0.93, 2.02)
High CRP 133/44/15 2.20 (1.52, 3.19) 1.86 (1.24, 2.78) 1.71 (1.13, 2.58) 1.66 (1.12, 2.46)
Model 1: Adjusted for age and sex.
Model 2: Adjusted for age, sex, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol,, triglycerides, body mass
index, smoking, DM, and family history of premature CHD.
Model 3: Adjusted for the Framingham Risk Score.
Table 5. Univariate and Multivariable Linear Regression Demonstrating Association of CRP With Extent of
Any, Noncalcified, Calcified, and Mixed Plaques
CRP Category
Plaque Extent;
Mean (SD)
Unadjusted
OR (95% CI)
Model 1
OR (95% CI)
Model 2
OR (95% CI)
Model 3
OR (95% CI)
Any plaque type
Intermediate CRP 0.41 (0.89) 0.13 (0.01, 0.27) 0.02 (0.11, 0.15) 0.00 (0.13, 0.13) 0.05 (0.08, 0.18)
High CRP 0.65 (1.21) 0.36 (0.21, 0.51)* 0.23 (0.09, 0.37)* 0.21 (0.07, 0.35)* 0.21 (0.07, 0.35)*
Noncalcified
Intermediate CRP 0.09 (0.38) 0.01 (0.05, 0.07) 0.01 (0.08, 0.05) 0.02 (0.09, 0.04) 0.01 (0.07, 0.05)
High CRP 0.18 (0.57) 0.10 (0.03, 0.16)* 0.07 (0.00, 0.14) 0.06 (0.01, 0.13) 0.06 (0.00, 0.06)
Mixed
Intermediate CRP 0.20 (0.58) 0.12 (0.04, 0.20)* 0.08 (0.00, 0.15) 0.07 (0.01, 0.14) 0.08 (0.01, 0.16)*
High CRP 0.30 (0.72) 0.22 (0.14, 0.30)* 0.17 (0.09, 0.24)* 0.16 (0.08, 0.24)* 0.15 (0.07, 0.23)*
Calcified
Intermediate CRP 0.12 (0.39) 0.01 (0.08, 0.07) 0.05 (0.12, 0.02) 0.05 (0.12, 0.03) 0.03 (0.11, 0.04)
High CRP 0.17 (0.61) 0.05 (0.03, 0.13) 0.00 (0.08, 0.07) 0.00 (0.08, 0.08) 0.00 (0.08, 0.08)
 indicates beta-estimate: Predicted increase in number of segments with plaque.
*Statistically significant.
Reference group is low-normal CRP.
Model 1: Adjusted for age and sex.
Model 2: Adjusted for age, sex, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol,, triglycerides, body mass
index, smoking, DM, and family history of premature CHD.
Model 3: Adjusted for the Framingham Risk Score.
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greater amounts of CRP-stained cells in samples from culprit
lesions of unstable angina patients as compared with lesions
from patients with stable angina. They also found an in-
creased rate of restenosis on follow-up angiography in the
elevated CRP group, suggesting that CRP might be related to
plaque vulnerability. Providing further support for this hy-
pothesis, in a postmortem study, Burke et al36 demonstrated
that elevated serum CRP correlated with an increased number
of thin-cap fibroatheromas (TCFA), a key component of vulner-
able plaque.
The relationship between coronary plaque subtypes as
evidenced by CCTA and cardiovascular outcomes has also
been examined. In a group of 71 patients with acute coronary
syndrome (ACS) or stable angina, Motoyama et al37 demon-
strated an association between NCAP and the occurrence of
ACS. In contrast to our study, they did not have a separate
MCAP group and only classified plaques as either CAP or
NCAP. Mixed calcified plaque has also been associated to
increased cardiovascular risk. Lin et al38 showed that MCAP
predicted severely abnormal perfusion abnormalities by
single-photon emission CT and Pundziute et al39 showed that
MCAP was a significant predictor for coronary events.
Further supporting the notion that NCAP and MCAP are
associated with increased cardiovascular events, Pundziute et
al15 demonstrated that CAP was more prevalent in stable
coronary disease, whereas NCAP and MCAP were predom-
inantly found in patients presenting with ACS. Additionally,
they found that TCFA were more prevalent in those pres-
enting with ACS, and, most importantly, they showed that
TCFA were more frequently observed in lesions classified as
MCAP. These results suggest that MCAP might be associated
with an increased cardiovascular risk due to the increase
burden of TCFA. Finally, in a population of symptomatic
subjects, Hauleiter et al40 showed that persons with NCAP
had increased levels of CRP as compared with those with
CAP. Unlike their study, ours included a prespecified MCAP
group, and our patient population was asymptomatic.
It has been clearly demonstrated that both elevated levels
of CRP and specific plaque subtypes are associated to poor
cardiovascular outcomes. Understanding how CRP and vul-
nerable plaques are related and using imaging techniques to
assess this relationship may enable the identification of
vulnerable patients.
In this regard, Avanzas et al41 found that elevated CRP
levels correlated with the presence of multiple angiographically
complex coronary stenosis, and Tanaka et al42 determined that
elevated levels of CRP were associated with plaque rupture in
patients presenting with ACS. Although the relationship be-
tween CRP and plaque subtypes has been studied using tradi-
tional angiography and intravascular ultrasound, our study is the
first to assess this relationship by means of CCTA in a large
group of asymptomatic individuals.
The potential clinical utility of identifying asymptomatic
patients with high-risk coronary plaque subtypes does not
necessarily justify the contrast and radiation exposure asso-
ciated with CCTA. Unlike CCTA, measuring CRP is rela-
tively safe, and, although not currently recommended for all
asymptomatic subjects at low risk for cardiovascular events,
we demonstrated that elevated CRP levels allowed for the
identification of high-risk coronary plaques in an asymptom-
atic population. Other studies are necessary to determine the
efficacy and cost-effectiveness of measuring CRP in all
asymptomatic subjects. Our results should be considered
hypothesis-generating and should not be used to justify the
use of CCTA in an asymptomatic patient population. Our
findings suggest that the increased risk observed in persons
with higher levels of CRP could be due, at least in part, to a
greater burden of MCAP, a plaque subtype frequently asso-
ciated with determinants of plaque instability.
In our study, the mean radiation exposure of CCTA was
13.20.8 mSv. Although there is a small chance (1 in 2000)
of development of a fatal cancer as the result of a 10-mSv CT
study,43 other studies have demonstrated that 64-slice MDCT
is associated with a nonnegligible risk of cancer.44 Addition-
ally, with the advent of new MDCT technology, the radiation
dose for CTA could be minimized to the level of background
radiation (3 mSv).45
Our study has several limitations. This analysis is one of a
cross-sectional nature, so it is not possible to make causal
inferences. We studied asymptomatic subjects; therefore our
results may not apply to symptomatic individuals. Because
our patients were self-referred, there is a possibility of
selection bias. Although the internal validity of our results
should not be affected by selection bias, a population-based
study design would be expected to have less selection bias
and improved external validity. Additionally, our cohort
is composed exclusively of Korean individuals, which affects
the generalizability of our results (for example, our subjects
had lower body mass index values than the general US
population). Because we categorized coronary plaque sub-
types into NCAP, MCAP, or CAP as opposed to quantifying
in a continuous manner the burden of calcified and noncal-
cified plaque components, there is a chance of misclassifica-
tion. Finally, because plaque was modeled in various manners
and we used a 5% significance criterion, we cannot com-
pletely rule out the possibility of some false-positive results.
Despite these limitations, it is important to note that the
way in which we categorized plaque subtypes has been
accepted in the literature.38,39 We are not aware of a mecha-
nism to directly quantify the noncalcified component of
plaques. Because of the current radiation exposure associated
to CCTA, the administration of a contrast agent, and the lack
of imaging protocol standardization in clinical practice, there
are no data justifying the use of CCTA in asymptomatic
patients. We do fully support the use of CCTA as a research
tool to better understand the significance of the different
coronary plaque subtypes as well as other vessel changes
observed with occult coronary artery disease. We believe that
identifying these characteristics may help improve risk strat-
ification efforts.
Conclusions
In an asymptomatic population, increasing levels of CRP are
associated with the prevalence of any plaque and MCAP, the
extent of MCAP, and the presence of significant coronary
stenosis. Our study results suggest that the increased cardio-
vascular risk associated with increased levels of CRP could
be due in part to a higher prevalence of MCAP, which has
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been shown to possess some of the key elements observed in
unstable plaques. The identification of MCAP using CCTA
could potentially lead to better risk stratification. Future
prospective studies are needed to establish a causal associa-
tion between the presence of MCAP and acute coronary
events.
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CLINICAL PERSPECTIVE
Coronary computed tomography angiography (CCTA) has been shown to be a sensitive and specific tool for the detection
of significant coronary stenosis and has also allowed for the visualization and characterization of coronary plaque subtypes.
Several studies have demonstrated that CCTA can provide prognostic information in patients with suspected coronary heart
disease. Studies have also provided insight as to what specific plaque subtypes and characteristics might be associated with
poor outcomes. Concurrently, high-sensitivity C-reactive protein (hsCRP) has also been proposed as a method of
identifying individuals at higher cardiovascular risk and has been shown to allow for the independent and improved risk
stratification beyond traditional risk scoring systems. We sought to analyze the relationship between elevated levels of
hsCRP and plaque subtypes as identified by CCTA. Increasing levels of hsCRP were found to be associated with the
prevalence and extent of any mixed calcified plaque and the presence of significant coronary stenosis. Our results suggest
that the increased cardiovascular risk associated with increased levels of hsCRP could be due, at least in part, to a higher
prevalence of mixed calcified plaque, which has been shown to have some of the key elements observed in unstable
coronary plaques.
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